

1 **Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the**
2 **Comirnaty® COVID-19 vaccine in nursing home residents**

3 Beatriz Sánchez-Sendra¹, Eliseo Albert², Joao Zulaica¹, Ignacio Torres², Estela
4 Giménez², Pilar Botija³, María José Beltrán⁴, Celia Rodado⁵, Ron Geller^{1†} and David
5 Navarro^{2,6†}

6 ¹*Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC,*
7 *46980, Valencia, Spain.*

8 ²*Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute,*
9 *Valencia, Spain.*

10 ³*Dirección de Atención Primaria, Departamento de Salud Clínico-Malvarrosa,*
11 *Hospital Clínico Universitario de Valencia, Valencia, Spain.*

12 ⁴*Dirección de Enfermería, Departamento de Salud Clínico-Malvarrosa, Hospital*
13 *Clínico Universitario de Valencia, Valencia, Spain.*

14 ⁵*Comisión Departamental de control de Residencias. Departamento de Salud València*
15 *Clínico Malvarrosa.*

16 ⁶*Department of Microbiology, School of Medicine, University of Valencia, Valencia,*
17 *Spain*

18

19 †Both senior authors contributed equally to the current work.

20 **Correspondence:** David Navarro, Microbiology Service, Hospital Clínico
21 Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of
22 Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010

1 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; E-mail:
2 david.navarro@uv.es.

3 **Running title:** Neutralizing Ab vs. SARS-CoV-2 variants

4 **ABSTRACT** (150 words)

5 Immunosenescence may impact the functionality and breadth of vaccine-elicited
6 humoral immune responses. The ability of sera to neutralize the SARS-CoV-2 spike
7 protein (S) from Beta, Gamma, Delta, and Epsilon variants of concern (VOCs) relative
8 to the ancestral Wuhan-Hu-1 strain was compared in Comirnaty® COVID-19-
9 vaccinated elderly nursing home residents (n=30) or younger individuals (n=18) and
10 non-vaccinated individuals who recovered from severe COVID-19 (n=19). In all
11 groups, some participants lacked NtAb against one or more VOCs, mainly the Beta
12 variant (15-20%). Serum NtAb titers were lowest against the Beta variant followed by
13 Gamma, Epsilon, and Delta variants. Fold change reduction in NtAb titers relative to
14 the ancestral strain was greatest for the Beta variant (6.7-18.8) followed by Gamma
15 (3.6-6.2), Epsilon (2.9-5.8), and Delta (3.5-4.3) variants, regardless of the study group
16 considered. In summary, older age, frailty, and concurrence of co-morbidities had no
17 impact on the serum NtAb activity profile against SARS-CoV-2 VOCs.

18 **Key words:** SARS-CoV-2 variants; Neutralizing antibodies; Comirnaty® COVID-19
19 vaccine; Nursing home residents

20 **INTRODUCTION** (2365 word)

21 Coronaviruses encode a proof-reading mechanism to minimize sequence variation in the
22 long RNA genomes that may compromise their survival in nature [1]. Nevertheless,
23 generation of variants during coronavirus replication in humans unfailingly ensues [2].
24 Many SARS-CoV-2 variants have emerged since its appearance late in 2019, some of

1 which may pose a threat to pandemic control due to their relative resistance to
2 neutralizing activity of antibodies elicited following natural infection or vaccination
3 with the original SARS-CoV-2 isolate (Wuhan/Hu-1); these variants, termed variants of
4 concern (VOC), incorporate amino acid substitutions or deletions in critical locations
5 within the virus Spike (S) protein [3]. The Comirnaty® mRNA COVID-19 vaccine
6 encodes the ancestral strain S protein in a pre-fusion conformation [4]. Several studies
7 have shown a decreased ability of serum antibodies elicited by this vaccine to neutralize
8 a number of VOCs compared to the original strain, most notably Beta (B.1.351),
9 Gamma (P.1), and more recently Delta (B.1.617.2)[5-12]. Nevertheless, elderly people
10 with frailty and co-morbidities, who are at the highest risk to develop severe forms of
11 COVID-19, were either not included or underrepresented in these studies. Since
12 immunosenescence may be detrimental to the functionality and breadth of vaccine-
13 elicited humoral immune responses [13], profiling of cross-neutralizing activity against
14 VOCs of sera from fully vaccinated elderly people is of major public health interest. In
15 the current work, we address this issue by comparing the neutralizing capacity of sera
16 from Comirnaty® COVID-19-vaccinated nursing home residents with that of sera from
17 younger and seemingly healthy vaccinated individuals and non-vaccinated individuals
18 who recovered from severe COVID-19.

19 **MATERIAL AND METHODS**

20 **Study groups**

21 In this observational retrospective study, three population groups were considered.
22 Group 1 included 30 nursing home (NH) residents with frailty and one or more co-
23 morbidities (23 females), randomly selected from one NH affiliated to the Clínico-
24 Malvarrosa Health Department, Valencia (Spain), aged a median of 90 years (range 64-
25 100). Twenty-two were SARS-CoV-2 naïve, as judged by a lack of antibodies targeting

1 the SARS-CoV-2 nucleoprotein (N), and 8 had contracted COVID-19 requiring
2 hospitalization prior to receiving the first dose of the Comirnaty® COVID-19 vaccine,
3 as determined by positive RT-PCR results in nasopharyngeal specimens and the
4 detection of SARS-CoV-2 N antibodies. In all cases, the variant Wuhan/D614G was
5 involved, as determined by whole-genome sequencing (not shown). All participants in
6 this group were vaccinated on the same day and the sera were drawn at a median of 35
7 days after the second vaccine dose.

8 Group 2 comprised 18 healthy individuals (14 females) aged a median of 47.5 years
9 (range, 26-62). No molecular or serological evidence of prior SARS-CoV-2 infection
10 was available from any of these participants, whose sera were drawn at a median of 15
11 days since the completion of the vaccination schedule (range, 13-18).

12 Group 3 included 19 individuals (7 females; median age, 63 years; range 40-80) who
13 were infected with the Wuhan/D614G strain (determined by whole-genome sequencing;
14 data not shown), required hospitalization either in clinical wards or intensive care units,
15 and eventually recovered from severe COVID-19. Sera from these individuals were
16 obtained at a median of 105 days (range, 12-147) after molecular diagnosis of SARS-
17 CoV-2 infection.

18 Group 4 (control group) included 10 healthy unvaccinated individuals (median age 52
19 years; range, 35-60 years), with no evidence of prior SARS-CoV-2 infection.

20 The study was approved by INCLIVA Research Ethics Committee. Informed consent
21 was obtained from all participants.

22 **Generation of SARS-CoV-2 with variant spikes**

23 We introduced mutations in a mammalian expression vector encoding a codon-
24 optimized SARS-CoV-2 S sequence from the Wuhan reference strain [14]. First, the

1 D614G mutation was introduced by site-directed mutagenesis. Subsequently, additional
2 site-directed mutagenesis and/or the cloning of synthetic fragments harboring the
3 mutations (Gblocks, IDT) was performed to introduce all mutations using the
4 NEBuilder HiFi DNA assembly mix (NEB). For the Beta variant (PANGO Lineage:
5 B.1.351; mutations D80A, L241Del, L242Del, A243Del, E484K, N501Y, D614G, and
6 A701V), a synthetic fragment encoding mutations D80A, L241Del, L242Del, A243Del,
7 E484K, and N501Y was cloned, and the A701V mutation introduced by site-directed
8 mutagenesis. For the Gamma variant (PANGO Lineage: P1 or B.1.1.28.1; mutations
9 L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I,
10 and V1176F), a synthetic fragment encoding mutations (L18F, T20N, P26S, D138Y,
11 R190S, K417T, E484K, and N501Y) was cloned, and additional mutations H655Y,
12 T1027I, and V1176F were inserted by site-directed mutagenesis. For the Delta variant
13 (PANGO lineage: B.1.617.2; mutations T19R, del157/158, L452R, T478K, D614G,
14 P681R, and D950N) mutations were introduced by site-directed mutagenesis. Finally,
15 for the Epsilon variant (PANGO lineages B.1.427/B.1.429; mutations S13I, W152C,
16 L452R, D614G), a synthetic fragment encoding mutations S13I, W152C, and L452R
17 was cloned. All plasmids were verified by Sanger sequencing.

18 **Virus neutralization assay**

19 The neutralization capacity of circulating antibodies (NtAb) against the SARS-CoV-2 S
20 protein was assessed using a GFP-expressing vesicular stomatitis virus pseudotyped
21 with different Spike variants as previously described [15], but using A549-ACE2-
22 TMPRSS2 cells (InvivoGen catalog code a549-hace2tps). All tests were done in
23 duplicate using 5-fold serum dilutions ranging from 1:20 to 1:62,500, with ~1,000 focus
24 forming units per well. Following 16 hours of infection, the GFP signal in each well
25 was quantified using a live-cell microscope (Incucyte S3, Sartorius). Background

1 fluorescence from uninfected wells was subtracted from all infected well, and the GFP
2 fluorescence in each antibody-treated dilution was standardized to the average
3 fluorescence observed in mock-treated wells. Any value resulting in a relative GFP
4 signal of <0.001 versus was assigned a value of 0.001 to eliminate negative values.
5 Finally, the reciprocal antibody dilution resulting in 50% virus neutralization was
6 calculated using the `drc` package (version 3.0-1) in R via a three-parameter
7 log-logistic regression model (LL.3 model). For the Beta, Gamma, and Epsilon
8 variants, all assays for the same serum were performed simultaneously with the Wuhan
9 reference strain unless neutralization was repeated due to high variability. As the Delta
10 variant was performed subsequently, we retested each serum was against both Delta and
11 the Wuhan strains unless no neutralization of Wuhan was observed in the previous
12 assays. Sera testing negative (undetectable) were arbitrarily ascribed a titer of 1/20.

13 **Quantitation of SARS-CoV-2 receptor binding domain-reactive antibodies**

14 Total antibodies (IgG and IgM) against the SARS-CoV-2 S protein receptor-binding
15 domain (RBD) were measured by Roche Elecsys® electrochemiluminescence sandwich
16 immunoassays (Roche Diagnostics, Pleasanton, CA, USA). The limit of detection of the
17 assay is 0.4 IU/ml and its quantification range is between 0.8 and 250 IU/ml. Plasma
18 specimens were further diluted (1/10) for antibody quantitation when appropriate. The
19 assay is calibrated with the first WHO International Standard and Reference Panel for
20 anti-SARS-CoV-2 antibody [16]. Cryopreserved plasma (-20 °C) specimens were
21 thawed and assayed in singlets. Plasma specimens were diluted (1/10) for antibody
22 quantitation when appropriate.

23 **Statistical methods**

1 Geometric mean titers (GMTs) are reported throughout the study. Comparison of GMTs
2 and medians across groups was carried out by the Student's t-test or the Mann-whitney
3 U-test, as appropriate. Correlations between variables of interest were calculated by the
4 Spearman Rank test. Frequency comparison across groups was performed using
5 Fisher's exact test. Two-sided exact P values were reported. A P value <0.05 was
6 considered statistically significant. The analyses were performed using SPSS version
7 20.0 (SPSS, Chicago, IL, USA).

8 **RESULTS**

9 **Detection of SARS-CoV-2-RBD and neutralizing antibodies in participants and** 10 **controls**

11 Antibodies targeting the SARS-CoV-2 RBD were detectable in all but one (belonging to
12 group 3) out of the 67 participants and in none of the controls. Antibody levels across
13 the study groups, shown in Figure 1, were found to differ significantly, with nursing
14 home residents displaying higher levels as compared to that in participants from the
15 other two study groups. Similarly, using a pseudotyped vesicular stomatitis virus
16 system, NtAb against the ancestral strain were detected in all but one (belonging group
17 3) participants and in none of the controls. Measurable NtAb against the different
18 SARS-CoV-2 VOCs included in the study were found at variable frequencies depending
19 upon the study group and the virus variant considered (Table 1). In all groups, some
20 participants lacked NtAb against one or more VOCs, most notably the Beta variant (15-
21 20%). As for vaccinated individuals (groups 1 and 2), no significant differences in the
22 detection rate of NtAb for any SARS-CoV-2 VOCs were found ($P \geq 0.5$) (Table 1).

23 **Antibody neutralizing titers against SARS-CoV-2 S variants across study groups**

1 Overall, all VOCs were neutralized to a lesser extent than the ancestral strain (Figure 2).
2 Specifically, serum NtAb titers were lowest against the Beta variant followed by
3 Gamma, Epsilon, and Delta variants, although wide ranges were observed for all
4 variants. This pattern was shared by all study groups (Figure 3 and Table 2).
5 Accordingly, fold change reduction in NtAb titers relative to the ancestral strain was
6 greatest for the Beta variant (6.7-18.8) followed by Gamma (3.6-6.2), Epsilon (2.9-5.8),
7 and Delta (3.5-4.3) variants. The decrease in NtAb titers for any of SARS-CoV-2 VOCs
8 was not significantly different across comparison groups (Supplementary Figure 1).

9 **Correlation between SARS-CoV-2 neutralizing and anti-RBD antibodies**

10 The degree of correlation between levels of SARS-CoV-2 antibodies neutralizing
11 SARS-CoV-2 VOCs and total anti-RBD antibodies across the different population
12 groups was examined next. Overall, the correlation between these two parameters was
13 best for the ancestral strain and slightly decreased for all VOCs (Supplementary Figure
14 1). Of interest, this pattern was similar for both the vaccinated participants from nursing
15 home residents and healthy controls (Supplementary Table 1).

16 **DISCUSSION**

17 Reduced neutralization of VOCs as compared to the ancestral Wuhan-Hu-1 strain has
18 been observed in sera from individuals that were fully vaccinated against SARS-CoV-2
19 or have recovered from infection by either the ancestral Wuhan or the Wuhan/D164G
20 SARS-CoV-2 strains [5-12,17-18]. This has been observed in both the full SARS-CoV-
21 2 virus or pseudotyped virus systems and is most notable for the Beta variant. As for
22 recipients of the Comirnaty® COVID-19 vaccine, this observation has been mostly
23 made in vaccine clinical trials participants and seemingly healthy health workers [5-12].
24 Here, using S-pseudotyped SARS-CoV-2 variants, we extend this finding to include

1 elderly nursing home residents, both in SARS-CoV-2 naïve participants and those
2 infected by the Wuhan/D614G variant prior to vaccination. In effect, one month after
3 the second vaccine dose, sera from fully vaccinated nursing home residents retained the
4 ability to neutralize VOCs in most cases, but did so to a lesser extent than the ancestral
5 strain, especially in the case of the Beta variant. Importantly, reduction in NtAb activity
6 against VOCs in this population group was not significantly different from that seen in
7 healthy fully-vaccinated controls (in sera obtained a median of two weeks after
8 vaccination) and unvaccinated individuals who had recovered from severe COVID-19
9 diagnosed within a median time of 3 months. Leaving aside participants who remained
10 unvaccinated and naturally contracted the infection, which are not strictly comparable to
11 vaccinees, our data strongly support the idea that older age, frailty, and concurrence of
12 co-morbidities in fully-vaccinated individuals had no impact on the serum NtAb activity
13 profile against VOCs, including Delta variant that currently dominates in many
14 countries. The reduction in NtAb activity for all VOCs relative to that observed for the
15 Wuhan-Hu-1 reference strain (fold-change reduction in NtAb activity) was higher for
16 all VOCs compared to other studies, especially the Beta variant. For example, using a
17 pseudotyped virus system, Liu et al. [5-7] reported a 2.7- and 1.4-fold reduction in the
18 NtAb activity against Beta and Delta variants, respectively, for sera from participants in
19 the Comirnaty® COVID-19 vaccine the trial, who were seemingly comparable to our
20 healthy vaccinated controls (13.1 and 3.0 fold reduction, respectively). In turn, using
21 live virus isolates in microneutralization assays, Lustig and colleagues [11] found fold
22 change reduction in NtAb titers of 10.4, 2.3, and 2.1 against the Beta, Gamma, and
23 Delta variants compared with the ancestral virus in health care workers fully vaccinated
24 with the Comirnaty® COVID-19 vaccine. Comparison of fold change reduction figures
25 across studies is not straightforward, due not only to differences between population

1 group characteristics, especially in terms of age, sex, comorbidities, and SARS-CoV-2
2 infection status prior to vaccination, but also to differences in the pseudotyped virus
3 platforms, the chosen S sequences used to represent each variant or the use of live
4 viruses. Despite these differences, a similar pattern of NtAb activity against VOCs can
5 be derived from these studies as well as our current work, with the Beta variant being
6 less efficiently neutralized than the ancestral strain, followed by the Gamma, Epsilon,
7 and Delta variants.

8 Levels of total antibodies binding SARS-CoV-2 RBD as quantitated by the Roche
9 Elecsys® electrochemiluminescence sandwich immunoassays strongly correlate with
10 NtAb titers against the ancestral SARS-CoV-2 strain [19,20]. Here we extended this
11 observation to those against Beta, Gamma, Delta, and Epsilon variants, suggesting that
12 SARS-CoV-2 RBD antibody levels measured by this assay may be a reliable proxy for
13 serum NtAb activity against these VOCs, regardless of the vaccinated population group
14 considered.

15 The relatively small sample size could be considered a limitation of the current study.
16 Also, a limitation inherent to the use of S-pseudotyped viruses is the inability to assess
17 the impact of variations in other viral genes outside of the S protein that could affect
18 sera neutralization.

19 In summary, herein we show that neutralizing activity of sera against SARS-CoV-2
20 variants carrying critical escape mutations in the S gene is decreased relative to the
21 ancestral strain in both qualitative and quantitative terms in nursing home residents
22 recently vaccinated with the Comirnaty® COVID-19 vaccine. Nevertheless, the fold
23 reduction in NtAb activity in this population group was not different from that seen in
24 vaccinated controls and recovered COVID-19 individuals who had not been vaccinated.
25 Importantly, among VOCs, the Delta variant that is currently predominant worldwide

1 was best neutralized by sera from participants in all study groups. Nevertheless, the
2 degree to which reduced neutralization activity of the different VOCs, and especially
3 the Delta variant, impact infection and/or disease in vaccinated nursing home residents
4 translate into diminished effective protection is currently under investigation.

5 **ACKNOWLEDGMENTS**

6 We are grateful to all personnel who work at nursing home residences affiliated with the
7 Clínico-Malvarrosa Health Department and at Clinic University Hospital, in particular
8 to those at the Microbiology laboratory, for their commitment in the fight against
9 COVID-19. Ignacio Torres holds a Río Hortega Contract (CM20/00090) from the
10 Carlos III Health Institute. Eliseo Albert holds a Juan Rodés Contract (JR20/00011)
11 from the Carlos III Health Institute. Estela Giménez holds a Juan Rodés Contract
12 (JR18/00053) from the Carlos III Health Institute. Ron Geller holds a Ramon y Cajal
13 Fellowship from the Spanish Ministry of Economy and Competitiveness (RYC-2015-
14 17517).

15 **FINANCIAL SUPPORT**

16 This research work was supported by a grant from the European Commission–
17 NextGeneration EU.

18 **CONFLICTS OF INTEREST**

19 The authors declare no conflicts of interest.

20 **AUTHOR CONTRIBUTIONS**

21 BS-S, EA, JZ, IT, and EG: Methodology and data validation. PB, MJB, CR: in charge
22 of implementing public health policies to combat SARS-CoV-2 epidemic at nursing
23 home residences affiliated to the Clínico-Malvarrosa Health Department. RG and DN:

1 Conceptualization, supervision, writing the original draft. All authors reviewed the
2 original draft.

3 **REFERENCES**

- 4 1. Smith EC, Blanc H, Surdel MC, Vignuzzi M, Denison MR. Coronaviruses lacking
5 exoribonuclease activity are susceptible to lethal mutagenesis: evidence for
6 proofreading and potential therapeutics. *PLoS Pathog.* **2013**;9:e1003565.
- 7 2. V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and
8 replication: implications for SARS-CoV-2. *Nat Rev Microbiol.* **2021**;19:155-170.
- 9 3. Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L. Novel SARS-CoV-2
10 variants: the pandemics within the pandemic. *Clin Microbiol Infect.* **2021**;27:1109-
11 1117.
- 12 4. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits
13 human antibody and TH1 T cell responses. *Nature.* **2020**;586:594-599.
- 14 5. Liu Y, Liu J, Xia H, et al. Neutralizing Activity of BNT162b2-Elicited Serum. *N*
15 *Engl J Med.* **2021**;384:1466-1468.
- 16 6. Liu Y, Liu J, Xia H, et al. BNT162b2-Elicited Neutralization against New SARS-
17 CoV-2 Spike Variants. *N Engl J Med.* **2021**;385:472-474.
- 18 7. Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other
19 SARS-CoV-2 variants. *Nature.* **2021**;596:273-275.
- 20 8. Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion,
21 E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nat Med.*
22 **2021**;27:620-621.

- 1 9. Jalkanen P, Kolehmainen P, Häkkinen HK, et al. COVID-19 mRNA vaccine induced
2 antibody responses against three SARS-CoV-2 variants. *Nat Commun.* **2021**;12:3991.
- 3 10. Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2
4 B.1.617 by vaccine and convalescent serum. *Cell.* **2021**;184:4220-4236.e13.
- 5 11. Lustig Y, Zuckerman N, Nemet I, et al. Neutralising capacity against Delta
6 (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2,
7 BioNTech/Pfizer) vaccination in health care workers, Israel. *Euro Surveill.*
8 **2021**;26:2100557.
- 9 12. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to
10 SARS-CoV-2 and circulating variants. *Nature.* **2021**;592:616-622.
- 11 13. Jergović M, Coplen CP, Uhrlaub JL, Nikolich-Žugich J. Immune response to
12 COVID-19 in older adults. *J Heart Lung Transplant.* **2021**:S1053-2498(21)02303-2.
- 13 14. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry
14 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease
15 Inhibitor. *Cell.* **2020**;181:271-280.e8.
- 16 15. Gozalbo-Rovira R, Gimenez E, Latorre V, et al. SARS-CoV-2 antibodies, serum
17 inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. *J*
18 *Clin Virol.* **2020**;131:104611.
- 19 16. Mattiuzzo G, Bentley EM, Hassall M, et al. Establishment of the WHO International
20 Standard and Reference Panel for anti-SARS-CoV-2 antibody. WHO/BS/2020.2403,
21 December 10, 2020.
- 22 17. Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by
23 SARS-CoV-2 spike protein variants. *Elife.* **2020**;9:e61312.

1 18. Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses
2 against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-
3 19/BNT162b2 vaccination. *Nat Med.* **2021**;27:1525-1529.

4 19. Higgins V, Fabros A, Kulasingam V. Quantitative measurement of anti-SARS-CoV-
5 2 antibodies: Analytical and clinical evaluation. *J Clin Microbiol.* **2021**; 59:e03149-20.

6 20. Poljak M, Oštrbenk Valenčak A, Štamol T, Seme K. Head-to-head comparison of
7 two rapid high-throughput automated electrochemiluminescence immunoassays
8 targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor
9 binding domain. *J Clin Virol.* **2021**;137:104784.

10 **FIGURE LEGENDS**

11 **Figure 1.** Whisker plots depicting initial anti-SARS-CoV-2 RBD total antibody levels,
12 as measured by the Roche Elecsys® electrochemiluminescence sandwich
13 immunoassays (Roche Diagnostics, Pleasanton, CA, USA), in nursing home residents
14 (Group 1), healthy individuals fully vaccinated with the Comirnaty® vaccine (Group 2)
15 and unvaccinated, COVID-19 recovered individuals that required hospitalization in
16 internal medicine or intensive care units (Group 3). *P* value for comparison across the
17 three groups is shown.

18 **Figure 2.** Neutralizing antibody titers against the SARS-CoV-2 ancestral strain
19 (Wuhan-Hu-1) and variants of concern Beta, Gamma, Delta and Epsilon in sera from
20 participants. *P* values for pairwise comparisons are shown.

21 **Figure 3.** Neutralizing antibody titers against the SARS-CoV-2 ancestral strain
22 (Wuhan-Hu-1) and variants of concern Beta, Gamma, Delta and Epsilon across study
23 groups: nursing home residents (Group 1), healthy individuals fully vaccinated with the

1 Comirnaty® vaccine (Group 2) and unvaccinated, COVID-19 recovered individuals that
2 required hospitalization in internal medicine or intensive care units (Group 3).

3 **Figure 4.** Overall correlation between neutralizing antibody titers and anti-SARS-CoV-
4 2 RBD total antibody levels, as measured by the Roche Elecsys®
5 electrochemiluminescence sandwich immunoassays (Roche Diagnostics, Pleasanton,
6 CA, USA), according to the SARS-CoV-2 S-variant. Rho and *P* values are shown.

7 **Supplementary Figure 1.** Fold change reduction in neutralizing antibody titers against
8 SARS-CoV-2 variants of concern as compared to the ancestral strain as a function of
9 the study group considered: nursing home residents (Group 1), healthy individuals fully
10 vaccinated with the Comirnaty® vaccine (Group 2) and unvaccinated, COVID-19
11 recovered individuals that required hospitalization in internal medicine or intensive care
12 units (Group 3).

Table 1. Detectable neutralizing antibodies against different SARS-CoV-2 variants across study groups

SARS-CoV-2 variant	Number of participants with detectable neutralizing antibodies /total participants (%) ^a		
	Group 1	Group 2	Group 3
Ancestral (Wuhan-Hu-1)	30/30 (100)	18/18 (100)	18/19 (94.7)
Beta	24/30 (80)	16/18 (88.9)	16/19 (84.2)
Gamma	27/30 (90)	17/18 (94.4)	17/19 (89.5)
Delta	28/30 (93.3)	18/18 (100)	17/19 (89.5)
Epsilon	28/30 (93.3)	17/18 (94.4)	17/19 (89.5)

^aGroup 1, nursing home residents fully vaccinated with the Comirnaty® vaccine; Group 2, healthy individuals fully vaccinated with the Comirnaty® vaccine; Group 3, unvaccinated, COVID-19 recovered individuals that required hospitalization in internal medicine or intensive care units.

Table 2. Serum Neutralizing antibody titers against SARS-CoV-2 variants across study groups


SARS-CoV-2 variant	Parameter	Study groups ^a		
		Group 1	Group 2	Group 3
Beta	GMT (SD)	238 (4,510)	124 (316)	122 (999)
	Mean fold change reduction of NtAb titer (CI 95%) ^b	18.8 (109.1)	13.1 (6.9)	6.7 (84.9)
Gamma	GMT (SD)	722 (8,612)	256 (435)	225 (1607)
	Mean fold change reduction of NtAb titer (CI 95%) ^b	6.2 (9.1)	6.3 (6.6)	3.6 (4.8)
Delta	GMT (SD)	1,037 (67,237)	543 (1,138)	231 (1,162)
	Mean fold change reduction of NtAb titer (CI 95%) ^b	4.3 (10.9)	3.0 (0.6)	3.5 (4.1)
Epsilon	GMT (SD)	774 (6,778)	261 (324)	283 (1,869)
	Mean fold change reduction of NtAb titer (CI 95%) ^b	5.8 (7.7)	6.2 (6.6)	2.9 (2.2)
(Wuhan-Hu-1)	GMT (SD)	4,509 (48,923)	1,622 (2,259)	442 (2,083)


CI, confidence interval; GMT, geometric mean titer; NtAb, neutralizing antibodies; SD, standard deviation.

^aGroup 1, nursing home residents fully vaccinated with the Comirnaty® vaccine; Group 2, healthy individuals fully vaccinated with the Comirnaty® vaccine; Group 3, unvaccinated, COVID-19 recovered individuals that required hospitalization in internal medicine or intensive care units.


^bRelative to the NtAb titer against WA1/2020.

anti-SARS-CoV-2 RBD
(Total antibody)
(IU/ml)






Group 1



Group 2



Group 3

